Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs

详细信息    查看全文

• 作者：Lin Tao^a ; ^b ; ^c ; ¹ ; Feng Zhu^d ; ¹ ; Feng Xu^e ; Zhe Chen^f ; Yu Yang Jiang^a ; ^b ; ^{jiangyy@sz.tsinghua.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Yu Zong Chen^c ; ^{phacyz@nus.edu.sg" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Afatinib (Pubmed CID ; 10184653) ; Erlotinib (Pubmed CID ; 176870) ; Gefitinib (Pubmed CID ; 123631) ; Pazopanib (Pubmed CID ; 10113978) ; XL647 (Pubmed CID ; 10458325) ; Lenvatinib (Pubmed CID ; 9823820)
• 刊名：Pharmacological Research
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：102
• 期：Complete
• 页码：123-131
• 全文大小：3306 K

文摘

Recent investigations have suggested that anticancer therapeutics may be enhanced by co-targeting the primary anticancer target and the corresponding drug escape pathways. Whether this strategy confers statistically significant clinical advantage has not been systematically investigated. This question was probed by the evaluation of the clinical status and the multiple targets of 23 approved and 136 clinical trial multi-target anticancer drugs with particular focus on those co-targeting EGFR, HER2, Abl, VEGFR2, mTOR, PI3K, Alk, MEK, KIT, and DNA topoisomerase, and some of the 14, 7, 13, 20, 6, 5, 7, 2, 4 and 10 cancer drug escape pathways respectively. Most of the approved (73.9%) and phase III (75.0%), the majority of the Phase II (62.8%) and I (53.6%), and the minority of the discontinued (35.3%) multi-target drugs were found to co-target cancer drug escape pathways. This suggests that co-targeting anticancer targets and drug escape pathways confer significant clinical advantage and such strategy can be more extensively explored.